# Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer

> **NCT04730999** · PHASE2 · COMPLETED · sponsor: **Gruppo Oncologico Italiano di Ricerca Clinica** · enrollment: 54 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Etoposide
- **DRUG:** Carboplatin
- **DRUG:** Bevacizumab
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT04730999
- **Lead sponsor:** Gruppo Oncologico Italiano di Ricerca Clinica
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-01
- **Primary completion:** 2023-06-01
- **Final completion:** 2024-06-19
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2024-07-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04730999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04730999, "Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04730999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*